Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: j_fir2 who wrote (2797)	5/17/1999 12:56:00 PM
From: sam	Respond to of 10280

Remember, J and J is still partnering with SEPR with regard to Norcisapride, a drug with much greater profit potential.

To: j_fir2 who wrote (2797)	5/17/1999 1:04:00 PM
From: Don Miller	Read Replies (1) \| Respond to of 10280

Further to your JNJ reaction thoughts- I posted this on Yahoo-Club: If I was doing business in this industry I would separate the isomer of the top three alternative drugs, then test those isomers on animals. By doing this I am trying to see what I could expect to compete with for the life of my patent, if I choose to take my alternative isomer forward. If I saw that Claritin's sedation issue could be eliminated with DCL, or my isomer would just equal claritin's impact, I would fold tent and go home. What has JNJ done? Has the market failed to appreciate what JNJ has said about the other SEPR antihistamines, and the small remainder of this market that SEPR does not has an improvement patent issued or pending?